Indication
Treatment of adult patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients.

Medicine details

Medicine name:
trabectedin (Yondelis)
SMC ID:
SMC2210
Pharmaceutical company
Immedica
BNF chapter
Malignant disease and immunosuppression
Submission type
Resubmission
Status
Publication due date:
Q4 2019
SMC meeting date:
Q4 2019
Patient group submission deadline:
02 September 2019